Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

608 - 3SBio

Next Previous
Drug Profile

608 - 3SBio

Latest Information Update: 21 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 3SBio
  • Developer 3SBio; Sunshine Guojian Pharmaceutical
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action IL17A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Plaque psoriasis
  • Phase II Axial spondyloarthritis
  • No development reported Rheumatoid arthritis

Most Recent Events

  • 22 Mar 2024 Phase-II clinical trials in Axial spondyloarthritis in China (SC) (NCT06222671)
  • 08 Mar 2024 Sunshine Guojian Pharmaceutical plans to initiate a phase III trial for Plaque Psoriasis in China (SC, Injection) (NCT06299982)
  • 01 Feb 2024 Sunshine Guojian Pharmaceutical plans a phase II trial in Ankylosing Spondylitis in China (SC, Injection) in March 2024 (NCT06242652)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top